Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Anika Therapeutics

This article was originally published in The Gray Sheet

Executive Summary

Anika Therapeutics: Plans to file a premarket approval application with FDA "by the end of the year" for its Orthovisc intra-articular hyaluronic acid injection for treatment of osteoarthritis of the knee. Results of a just-completed randomized clinical study of 226 patients conducted at 10 centers in the U.S. are "promising," the firm states. Two HA products for osteoarthritis of the knee recently received FDA approval -- Fidia's Hyalgan and Biomatrix' Synvisc ("The Gray Sheet" Aug. 18, p. 6)...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts